f SGLT-2 Inhibitors as an Effective Treatment for Type 2 Diabetes Mellitus, Hypertension, and Hyperuricemia - A Mechanistic Perspective

References

1. Salvatore T. Galiero R. Caturano A. Rinaldi L. Di Martino A. Albanese G. Di Salvo J. Epifani R. Marfella R. Docimo G. Lettieri M. Sardu C. Sasso F.C. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. Int. J. Mol. Sci. 2022 23 7 3651 10.3390/ijms23073651 35409011
   [Google Scholar]
2. Fonseca-Correa J.I. Correa-Rotter R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: A review. Front. Med. 2021 8 777861 10.3389/fmed.2021.777861 34988095
   [Google Scholar]
3. Pereira M.J. Eriksson J.W. Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs 2019 79 3 219 230 10.1007/s40265‑019‑1057‑0 30701480
   [Google Scholar]
4. Saisho Y. SGLT2 inhibitors: The star in the treatment of type 2 Diabetes? Diseases 2020 8 2 14 10.3390/diseases8020014 32403420
   [Google Scholar]
5. Ansary T.M. Nakano D. Nishiyama A. Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int. J. Mol. Sci. 2019 20 3 629 10.3390/ijms20030629 30717173
   [Google Scholar]
6. Adam C.A. Anghel R. Marcu D.T.M. Mitu O. Roca M. Mitu F. Impact of sodium–glucose cotransporter 2 (SGLT2) inhibitors on arterial stiffness and vascular aging—what do we know so far? (A narrative review). Life 2022 12 6 803 10.3390/life12060803 35743834
   [Google Scholar]
7. Herat L.Y. Magno A.L. Rudnicka C. Hricova J. Carnagarin R. Ward N.C. Arcambal A. Kiuchi M.G. Head G.A. Schlaich M.P. Matthews V.B. SGLT2 inhibitor–induced sympathoinhibition. JACC Basic Transl. Sci. 2020 5 2 169 179 10.1016/j.jacbts.2019.11.007 32140623
   [Google Scholar]
8. Chino Y. Samukawa Y. Sakai S. Nakai Y. Yamaguchi J. Nakanishi T. Tamai I. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm. Drug Dispos. 2014 35 7 391 404 10.1002/bdd.1909 25044127
   [Google Scholar]
9. Lai S.W. Hwang B.F. Kuo Y.H. Liu C.S. Liao K.F. Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: A systematic review and meta-analysis. Front. Endocrinol. (Lausanne) 2023 14 1158153 10.3389/fendo.2023.1158153 37288295
   [Google Scholar]
10. Zhang Q. Zhou S. Liu L. Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: A new meta-analysis. Diabetol. Metab. Syndr. 2023 15 1 118 10.1186/s13098‑023‑01092‑z 37280615
    [Google Scholar]
11. Halimi S. Vergès B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab. 2014 40 6 Suppl. 1 S28 S34 10.1016/S1262‑3636(14)72693‑X 25554069
    [Google Scholar]
12. Scheen A.J. SGLT2 inhibitors: Benefit/risk balance. Curr. Diab. Rep. 2016 16 10 92 10.1007/s11892‑016‑0789‑4 27541294
    [Google Scholar]
13. Mascolo A. Di Napoli R. Balzano N. Cappetta D. Urbanek K. De Angelis A. Scisciola L. Di Meo I. Sullo M.G. Rafaniello C. Sportiello L. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary. Front. Cardiovasc. Med. 2022 9 1010693 10.3389/fcvm.2022.1010693 36211584
    [Google Scholar]
14. Ueda P. Svanström H. Melbye M. Eliasson B. Svensson A.M. Franzén S. Gudbjörnsdottir S. Hveem K. Jonasson C. Pasternak B. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: Nationwide register based cohort study. BMJ 2018 363 k4365 10.1136/bmj.k4365 30429124
    [Google Scholar]
15. Pittampalli S. Upadyayula S. Mekala H.M. Lippmann S. Risks vs benefits for SGLT2 inhibitor medications. Fed. Pract. 2018 35 7 45 48 30766374
    [Google Scholar]
16. Matthews J. Herat L. Schlaich M.P. Matthews V. The impact of SGLT2 inhibitors in the heart and kidneys regardless of diabetes status. Int. J. Mol. Sci. 2023 24 18 14243 10.3390/ijms241814243 37762542
    [Google Scholar]
17. Caruso I. Giorgino F. SGLT-2 inhibitors as cardio-renal protective agents. Metabolism 2022 127 154937 10.1016/j.metabol.2021.154937 34808144
    [Google Scholar]
18. Gronda E. Lopaschuk G.D. Arduini A. Santoro A. Benincasa G. Palazzuoli A. Gabrielli D. Napoli C. Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis. Can. J. Physiol. Pharmacol. 2022 100 2 93 106 10.1139/cjpp‑2021‑0399 35112597
    [Google Scholar]